Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genetic testing could streamline heart therapy:

This article was originally published in Clinica

Executive Summary

A genetic test for the ACE (angiotensin converting enzyme) gene could predict which patients are likely to benefit from beta blockers in the treatment of congestive heart failure, according to a US study. Researchers from the University of Pittsburgh in Pennsylvania evaluated 328 patients with heart failure who were being treated with either ACE inhibitors, angiotensin receptor blockers or beta blockers. They found that patients with two deletion (D) alleles, known as ACE DD, had "dramatic benefits" when using beta blockers compared with the other medication. The study appeared in Circulation (March 27).





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts